Revvity schedules earnings call and raises guidance above range

Revvity Inc. (NYSE: RVTY) will release fourth quarter and full year 2025 financial results before market open on February 2, 2026, followed by a conference call at 8:00 a.m. ET the same day. Chief Executive Officer Prahlad Singh and Chief Financial Officer Max Krakowiak will host the call.

The health science solutions company provided preliminary fourth quarter 2025 results, projecting reported revenue growth of approximately 6% and organic revenue growth of approximately 4% compared to the same period last year. This translates to expected fourth quarter revenue of approximately $772 million.

For full year 2025, Revvity expects reported revenue growth of approximately 4% and organic revenue growth of approximately 3% year-over-year, resulting in anticipated revenue of approximately $2.855 billion.

The company also raised its full year 2025 adjusted earnings per share guidance, now expecting to exceed the upper end of its previous $4.90-$5.00 range provided in October 2025.

Singh will present at the J.P. Morgan Healthcare Conference at 9:45 a.m. PT on January 13, 2026. The presentation will be available via webcast, with accompanying slides posted to the company's investor relations website.

Revvity reported 2024 revenue of more than $2.7 billion and employs approximately 11,000 people. The company serves customers across pharmaceutical, biotech, diagnostic labs, academia and government sectors in more than 160 countries.

You May Also Be Interested In

• Wells Fargo Upgrades Portland General Electric Company (POR) to Overweight
• Citi raises Deere price target to $650, keeps Neutral rating
• ZKH Group Limited (ZKH) Reports Q2 EPS of $0.04